BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

REMARKS

Basis for the newly added claims 8-58 is found in claims 1-7 in the International Application and claims 1-13, as originally filed in the U.S. Serial No. 09/400,147, filed 09/22/1999, and in the specification, for example, in the Summary of the Invention, page 2, line 16-28, on page 2, line 31 to page 3, line 17, page 4, lines 10-29, page 12, line 1 to page 13, line 17, page 17, line 25 to page 18, line 12, and page 21, line 14 to page 22, line 5.

Newly added claims 8-58 are listed on Appendix I

No new matter will be added by entry of these claims.

Respectfully submitted

SCHERING-PLOUGH CORPORATION



Thomas D. Hoffman

APPENDIX I

Please cancel claims 1-7, and add the following claims:

(8) A method of treating or preventing allergic and inflammatory conditions of the skin or airway passages in a human in need of such treating or preventing while avoiding a food effect associated with other non-sedating antihistamines which comprises orally administering to said human under feed or fasted conditions an amount of desloratadine effective for such treating or preventing while avoiding a food effect on the bioavailability of desloratadine.

(9) The method of claim 8 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(10) The method of claim 8 wherein the amount of desloratadine is about 2.5 mg/day.

(11) The method of claim 8 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(12) The method of claim 8 wherein the amount of desloratadine is about 5 mg/day.

(13) The method of claim 8 wherein the desloratadine is administered in a tablet formulation.

(14) The method of claim 8 wherein the desloratadine is administered in a syrup formulation.

(15) The method of claim 8 wherein the allergic reaction is season allergic rhinitis, pernninal allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(16) A method of treating or preventing allergic and inflammatory conditions of the skin or airway passages in a human in need of such treating or preventing a which comprises orally administering to said human an amount of desloratadine effective for such treating

or preventing, while obtaining sustantially the same bioavailability of desloratadine under feed or fasted conditions.

(17) The method of claim 16 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(18) The method of claim 16 wherein the amount of desloratadine is about 2.5 mg/day.

(19) The method of claim 16 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(20) The method of claim 16 wherein the amount of desloratadine is about 5 mg/day.

(21) The method of claim 16 wherein the desloratadine is administered in a tablet formulation.

(22) The method of claim 16 wherein the desloratadine is administered in a syrup formulation.

(23) The method of claim 16 wherein the allergic reaction is season allergic rhinitis, pernninal allergic rhinitis, atopic dermatitis, urticaria or allergic asthma.

(24) A method of treating or preventing seasonal or perennial allergic rhinitis in a human in need of such treating or preventing while avoiding a food effect associated with non-sedating antihistamines which comprises orally administering to said human under feed or fasted conditions an amount of desloratadine effective for such treating or preventing while avoiding a food effect on the bioavailability of desloratadine.

(25) The method of claim 24 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(26) The method of claim 24 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(27) The method of claim 24 wherein the amount of desloratadine is about 2.5 mg/day.

(28) The method of claim 24 wherein the amount of desloratadine is about 5 mg/day.

(29) The method of claim 24 wherein the patient is suffering from seasonal allergic rhinitis.

(30) The method of claim 24 wherein the patient is suffering from perennial allergic rhinitis.

(31) The method of claim 24 wherein the desloratadine is administered in a tablet formulation.

(32) The method of claim 24 wherein the desloratadine is administered in a syrup formulation.

(33) A method of treating or preventing seasonal or perennial allergic rhinitis in a human in need of such treating or preventing a which comprises orally administering to said human an amount of desloratadine effective for such treating or preventing, while obtaining sustantially the same bioavailability of desloratadine under feed or fasted conditions.

(34) The method of claim 33 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(35) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(36) The method of claim 33 wherein the amount of desloratadine is about 2.5 mg/day.

(37) The method of claim 33 wherein the amount of desloratadine is about 5 mg/day.

(38) The method of claim 33 wherein the patient is suffering from seasonal allergic rhinitis.

(39) The method of claim 33 wherein the patient is suffering from perennial allergic rhinitis.

(40) The method of claim 33 wherein the desloratadine is administered in a tablet formulation.

(41) The method of claim 33 wherein the desloratadine is administered in a syrup formulation.

(42) A method of treating or preventing atopic dermatitis or urticaria in a human in need of such treating or preventing while avoiding a food effect associated with non-sedating antihistamines which comprises orally administering to said human under feed or fasted conditions an amount of desloratadine effective for such treating or preventing while avoiding a food effect on the bioavailability of desloratadine.

(43) The method of claim 42 wherein the amount of desloratadine is about 2.5 mg/day.

(44) The method of claim 42 wherein the amount of desloratadine is about 5 mg/day to about 15 mg/day.

(45) The method of claim 42 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(46) The method of claim 42 wherein the amount of desloratadine is about 5 mg/day.

(47) The method of claim 42 wherein the patient is suffering from atopic dermatitis.

(48) The method of claim 42 wherein the patient is suffering from urticaria.

(49) A method of treating or preventing atopic dermatitis or urticaria in a human in need of such treating or preventing a which comprises orally administering to said human an amount of desloratadine effective for such treating or preventing, while obtaining sustantially the same bioavailability of desloratadine under feed or fasted conditions.

(50) The method of claim 49 wherein the amount of desloratadine is in the range of about 2.5 mg/day to about 45 mg/day.

(51) The method of claim 49 wherein the amount of desloratadine is about 2.5 mg/day to about 45 mg/day.

(52) The method of claim 49 wherein the amount of desloratadine is about 2.5 mg/day.

(53) The method of claim 49 wherein the amount of desloratadine is about 5 mg/day to about 10 mg/day.

(54) The method of claim 49 wherein the amount of desloratadine is about 5 mg/day.

(55) The method of claim 49 wherein the desloratadine is administered in a tablet formulation.

(56) The method of claim 49 wherein the desloratadine is administered in a syrup formulation.

(57) The method of claim 49 wherein the patient is suffering from atopic dermatitis.

(58) The method of claim 49 wherein the patient is suffering from urticaria.